Strasbourg-based Dreampath Diagnostics, a HealthTech company focused on digitising workflows in anatomical pathology laboratories, today announced a growth investment from Summit Partners.
While financial terms of the transaction were not disclosed, the investment will support the company’s plans to accelerate global growth, scale operations and expand its commercial reach and product portfolio.
“Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval,” said Pablo Jordan, CEO and Co-founder of Dreampath Diagnostics. “Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We’re proud to partner with Summit to help us scale our impact and reach more patients around the world.”
Founded in 2012, Dreampath offers a patented suite of traceability solutions and consumables designed to automate and digitally transform the archiving and retrieval of tissue samples in pathology labs.
The company’s patented solutions combine purpose-built scanners, software and consumables to enable automated and error-free archiving and rapid retrieval of tissue samples, helping labs accelerate diagnostics, improve accuracy, and compliance.
Today, the company manages more than 250 million samples across over 500 labs in nearly 40 countries, serving a broad range of healthcare organizations, from hospitals and research institutions to commercial laboratories and cancer centers.
Dreampath’s integrated platform is protected by more than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to help eliminate the risk of patient sample loss. The company’s technology is tailored to specific stages of the pathology process and works with Dreampath’s proprietary software and consumables.
This closed-loop system reportedly helps labs archive and retrieve tissue samples with speed and precision, with a focus on improving sample traceability while reducing manual errors, retrieval times and operational burden.
Customers using the system have reported meaningful positive results, noting an 83% reduction in time spent archiving tissue samples.
“Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven’t meaningfully evolved in decades,” said Thomas Tarnowski, Managing Director at Summit Partners.
“Dreampath’s platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernisation of pathology infrastructure on a global scale,” he adds.
Dreampath has grown profitably and rapidly at a CAGR of more than 50% in recent years, driven by what the company describes as a “strong demand” for its platform across the U.S., EMEA and other global markets.
Dreampath’s customers include cancer centres and commercial laboratories.
“We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics,” added Jono Pagden, Principal at Summit Partners. “In our view, the company’s first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We’re proud to be their first institutional partner and excited to support the team in scaling their impact globally.”
Along with the investment, both Thomas Tarnowski and Jono Pagden from Summit Partners have joined the Dreampath Board of Directors.